clinical trial · NCT06745882
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 318
Non-small Cell Lung CancerCisplatinCarboplatinPemetrexedPembrolizumabAbraxanePaclitaxel
brief summary
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
started
Jun 13, 2025
primary completion
Jan 1, 2030
completion
Jan 1, 2030
last updated
Apr 2, 2026
official title
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol